A Mab A Case Study In Bioprocess Development __hot__ 🔥

At 2L scale, everything worked. At 200L, A Mab showed unexpected (from 2% to 8%). The root cause: inhomogeneous mixing led to localized high pH (>7.8) near the base addition port.

Our team selected a , the industry standard for mAbs due to its ability to perform human-like glycosylation—a critical factor for drug efficacy.

This case study highlights that integrating high-throughput cell screening with systematic DoE media optimization creates an adaptable upstream process. Concurrently, utilizing a robust, platformed three-step downstream purification template mitigates impurity risks early. This dual strategy minimizes timeline bottlenecks and guarantees compliance with strict regulatory frameworks.

With a selling price of $500/g, gross margin exceeded 70%. A Mab A Case Study In Bioprocess Development

principles from ICH guidelines (Q8, Q9, and Q10) could be applied to the development of a monoclonal antibody (mAb). International Society for Pharmaceutical Engineering (ISPE) Key Sections and Core Principles

For instance, a collaboration between Thermo Fisher Scientific and the Zurich University of Applied Sciences (ZHAW) demonstrated the scalable performance of optimized media and feed systems. Using in a fed-batch system and Gibco High-Intensity Perfusion (HIP) CHO Medium for perfusion workflows, the team successfully scaled processes from small volumes up to 50 L pilot scale, demonstrating consistent productivity and quality across scales.

Initial clones produced high titers but exhibited high levels of aggregation. An aggregated antibody can trigger an immune response, rendering the drug unsafe. At 2L scale, everything worked

Two sequential polishing steps were utilized to remove trace impurities like Host Cell Proteins (HCP), High Molecular Weight (HMW) aggregates, and residual DNA.

Methotrexate (MTX) amplification was used to select high-producing clones.

This case study on Monoclonal Antibody (mAb) development highlights how modern bioprocessing balances speed-to-market with high-quality yields. The Challenge Our team selected a , the industry standard

Fine depth filter to remove sub-micron particles and colloidal matter.

Using a 0.2 cm bed height of multimodal resin (Capto Adhere) at pH 5.5.

The case study provides detailed insights into both primary stages of production.

, specifically aggregates and fragments, which threatened the stability and efficacy of the final therapeutic. The Solution: A Quality by Design (QbD) Approach Instead of traditional trial-and-error, the team utilized a QbD framework to identify Critical Quality Attributes (CQAs): Upstream Optimization: By fine-tuning the feed strategy